Cyxone receive regulatory approval to start clinical Phase 2b study in RA
Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).“The approval is a very important milestone for us. Cyxone have now finally the possibility to initiate the greatest and foremost value-building activity ever in the company’s history. Receiving this green light from Poland,